Journal profile · Oncology
Bulletin du Cancer
ISSN 0007-4551 · eISSN 1769-6917 · John Libbey Eurotext · FRANCE · Monthly · Founded 1966
Bulletin du Cancer: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 0.97; hybrid open access; APC about USD 1,790; median 88 days to acceptance (109 articles, last 24 months); community-reported acceptance: about 75%; 267 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Bulletin du Cancer is published by John Libbey Eurotext and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Health, Medicine and Society, Cancer Treatment and Pharmacology and Colorectal Cancer Treatments and Studies, together about 18.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
The official journal of Société française du CancerWithout doubt, the 'Bulletin du Cancer' is the French language publication of reference in the field of cancerology. Official organ of the French Society of Cancer, this journal covers all the information available, whether in the form of original articles or review articles, but also clinical cases and letters to the editor, including various disciplines as onco-hematology, solids tumors, medical oncology, pharmacology, epidemiology, biology as well as fundamental research in cancerology. The journal proposes a clinical and therapeutic approach of high scientific standard and regular updates in knowledge are thus made possible. Articles can be submitted in French or English. The journal is indexed in the main international data bases and notably in: Abstracts/Biosis, CABS, Current Contents®/Life Sciences & Clinical Medicine, Excerpta Medica/Embase, Index Medicus/Medline, Medexpress, Science Citation Index, Pascal, Sociedad Iberoamericana de Informacíon Científica (SIIC).Le Bulletin du Cancer est indiscutablement la publication francophone de référence de langue française dans le domaine de la cancérologie. Organe officiel de la Société Française du Cancer, cette revue couvre la totalité de l'information disponible, qu'elle soit sous la forme d'articles originaux, de synthèses, de cas cliniques, de lettres et d'actualités. Une tribune libre est également disponible. Elle inclue des disciplines diverses comme l'onco-hématologie et les tumeurs solides, l'oncologie médicale, la pharmacologie, l'épidémiologie, la biologie et la recherche fondamentale en cancérologie. Le Bulletin du Cancer propose également une approche clinique et thérapeutique de haute tenue scientifique à la pointe des innovations. Une actualisation des connaissances est ainsi régulièrement possible. Le Bulletin du Cancer est indexé dans les principales bases de données internationales en particulier dans Abstracts/Biosis, CABS, Current Contents®/Life Sciences & Clinical Medicine, Excerpta Medica/Embase, Index Medicus/Medline, Medexpress, Science Citation Index, Pascal, Sociedad Iberoamericana de Informacíon Científica (SIIC).
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Jacques-Olivier BayPublisher website
Editorial board by country: none in mainland China; most named France 27 (27 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Health, Medicine and SocietyHealth Professions6.7%
- Cancer Treatment and PharmacologyMedicine6.4%
- Colorectal Cancer Treatments and StudiesMedicine5.4%
- Lung Cancer Treatments and MutationsMedicine5.3%
- Cancer Immunotherapy and BiomarkersMedicine5%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology4.8%
- Multiple and Secondary Primary CancersMedicine4.3%
- Healthcare Systems and PracticesHealth Professions4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCurrent ContentsPublisher website
Other: Index Medicus
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 0.97LetPub ·
- Impact factor (publisher)
- 1.1Publisher website ·
- CiteScore 2026-06
- 1.6LetPub ·
- CiteScore (publisher)
- 1.6Publisher website ·
- SJR 2026-06
- 0.28LetPub ·
- SNIP 2026-06
- 0.48LetPub ·
- h-index
- 35LetPub ·
- h-index
- 39OpenAlex ·
- i10-index
- 536OpenAlex ·
- 2-year mean citedness
- 0.45OpenAlex ·
- Self-citation rate
- 27.3%LetPub ·
- Share of gold OA articles
- 20.95%LetPub ·
Volume
- Articles per year
- 149LetPub ·
Articles by year OpenAlex count · 4,972 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 182 | 54 | 8 |
| 2025 | 267 | 63 | 116 |
| 2024 | 221 | 82 | 178 |
| 2023 | 237 | 91 | 425 |
| 2022 | 242 | 98 | 607 |
| 2021 | 272 | 99 | 1,267 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
88 daysMedian, submission to acceptance · P25–P75 49 days – 142 days
- Acceptance to online
- median 69 days (109 articles)
- Submission to online
- median 162 days
- Sample
- 109 articles with submission and acceptance dates (452 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
- Acceptance rate (publisher)
- 35%Publisher website ·
- Submission to first decision
- 15 daysPublisher website ·
- First decision after review
- 54 daysPublisher website ·
- Submission to acceptance
- 75 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 1,790 / EUR 1,630 / GBP 1,430 / JPY 222,010 | — | — | |
| Publisher website | USD 1,790 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 1,790 (excluding taxes). The amount you pay may be reduced during submission if applicable.Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Libbey Eurotext
- Country or region
- FRANCE
- Language
- French
- Frequency
- Monthly
- Founded
- 1966
- ISSN
- 0007-4551
- Electronic ISSN
- 1769-6917
- Society / sponsor
- Société française du Cancer Without doubt
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Bulletin du Cancer
What CAS zone is Bulletin du Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Bulletin du Cancer is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Bulletin du Cancer?
The latest impact factor listed by LetPub is 0.97; CiteScore 1.6, h-index 39.
How long does peer review take at Bulletin du Cancer?
Based on the dates recorded on 109 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 88 days (interquartile range 49–142 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 75%”; the journal's website gives an acceptance rate of 35%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Bulletin du Cancer based?
Of the 27 board members whose country the journal's board page names, none are in mainland China; the countries named most often are France (27). Counted from the institutions listed on the board page; for reference only.
Which databases index Bulletin du Cancer?
According to LetPub and DOAJ records, Bulletin du Cancer is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and Current Contents; that list has not been checked against each database.
Is Bulletin du Cancer open access, and what is the APC?
Bulletin du Cancer is a hybrid journal. For open-access publication: APC about USD 1,790.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .